FDA approves first therapy for patients with lung and thyroid cancers with a certain genetic mutation or fusion

Selpercatinib (competitive inhibitor of the rearranged during transfection receptor tyrosine kinase) was approved for RET fusion positive non-small cell lung cancer, and advanced medullary thyroid cancer. It was filed for regulatory review in the EU in February this year.


Biospace Inc.